Core Viewpoint - MicroTech Medical-B (02235.HK) has received approval for its LinX continuous glucose monitoring system in Brazil, targeting both adults and children for dynamic blood glucose monitoring [1] Market Potential - Brazil is identified as a core market in Latin America with significant potential, housing approximately 16.62 million diabetes patients aged 20-79, representing a prevalence rate of 10.7%, ranking sixth globally [1] - Diabetes-related expenditures in Brazil are projected to reach approximately $45.1 billion in 2024, making it the third highest globally, following the United States and China [1] Strategic Implications - The approval of the LinX continuous glucose monitoring system in Brazil is expected to significantly enhance the company's market presence in Latin America, laying a solid foundation for the scaling of international operations and revenue growth [1] - The company plans to continue focusing on the global development of diabetes monitoring, treatment, and management, while driving innovation in related technologies and products [1]
微泰医疗-B(02235.HK)：持续葡萄糖监测系统海外获批